MAGEB2

Across TCGA pan-cancer cohorts, MAGEB2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MAGEB2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAGEB2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAGEB2 expression acts as an unfavorable survival marker.

LSCC and HNSC are the cancer types where MAGEB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.826	0.957	.019	4	view →
HNSC	DFS	Median	III,IV	0.916	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MAGEB2–LSCC (OS)

Open the LSCC breakdown →